SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
about
The role of FLT3 in haematopoietic malignanciesClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewGenetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromeFLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Treatment of FLT3-ITD acute myeloid leukemia.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Effects of SU5416 and a vascular endothelial growth factor neutralizing antibody on wear debris-induced inflammatory osteolysis in a mouse model.Arsenic trioxide for the treatment of myelodysplastic syndromes.Novel therapies for patients with chronic myeloid leukemia.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Treating haemophilia A with recombinant blood factors: a comparison.Emerging treatments in acute myeloid leukaemia.Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia.Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.Biology and management of relapsed acute myeloid leukaemia.Angiogenesis and hematological malignancies.Emerging drugs for the treatment of myelodysplastic syndrome.The treatment of AML: current status and novel approaches.Recent advances in targeted therapy of human myelogenous leukaemia.Emerging Flt3 kinase inhibitors in the treatment of leukaemia.The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Autocrine VEGF loops, signaling pathways, and acute leukemia regulation.Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsA phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.Mechanisms of resistance to FLT3 inhibitors.Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.Bench to bedside targeting of FLT3 in acute leukemia.Clinical trials with anti-angiogenic agents in hematological malignancies.Targeted signal transduction therapies in myeloid malignancies.Lestaurtinib: a multi-targeted FLT3 inhibitor.FLT3 inhibitors: a story of the old and the new.Acute myeloid leukaemia in the elderly: a review.The clinical development of FLT3 inhibitors in acute myeloid leukemia.FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.Targeting the vascular endothelial growth factor in hematologic malignancies.
P2860
Q24319174-51364593-BA41-487A-8675-DC2184B728BBQ28301344-7807A19F-6B80-49CA-8F74-08AC5AF0E993Q33270804-5101FF70-FDC9-42E2-BA0C-DC16C319EB51Q33418285-64FACAA6-F12D-4B89-9B81-C643DE7D8D60Q34350591-5C988655-6446-44C1-B154-1C96FF531FE0Q34591403-68AEA70F-B7DB-4DEE-A7DA-0F494A49907AQ34636735-746341BC-C69A-44F0-B7F0-1ADA166AF03BQ34647741-6E5B16AC-1090-4EF7-A5FD-7F798A560A67Q35557415-7A7EA920-05CE-4C60-8BBC-575283706F26Q35688178-7D45332C-DE96-43A8-8099-14F12A889083Q35728742-AEE63ECC-9126-42FD-AB65-4A997E897277Q35750567-09E95443-E792-4366-A818-8E2DF3940860Q35779195-077B8E83-D851-4BAF-8FDA-CB96CE258CA4Q35779278-C2ED45F4-4417-4959-9170-8C07FF834837Q35782919-75DE3395-AD11-43BF-BDC9-2F4D439BD38DQ35921471-B30F6AC6-2EA7-401C-A901-C91F75E472A0Q35994847-31DE8BFB-CFCB-49AF-9A8C-5FF561D2AB41Q36085026-93E0D37B-95AE-4D6C-8D30-ECBEAA8D5BABQ36194525-4F441274-C041-4957-9072-CBC9FE6FA41BQ36219655-0450929E-EF26-4F31-8345-31131233939CQ36269943-6A9DAB98-2104-442A-8AF4-8EA8A820D6A5Q36318531-CCB333CB-8F9A-4990-B33F-4C8533D7E010Q36407425-2F3A4586-B46A-4662-99A3-6D4089D7E22AQ36526512-CB572CA9-CC02-4EE7-A947-5DD5F4924253Q36799838-B8A3249B-41DE-45A3-BF9D-4BDC7A688C7CQ37003553-9C129D0E-0A27-41FC-82C4-64C0DE290729Q37170610-B80E1E92-2622-456D-AED8-156CD51F96D5Q37183513-2370BC05-5F53-4931-90D2-6C8232AD52F0Q37375423-9819E5D0-287C-4D27-B238-C721F5FFC56CQ37416895-F9E8ED4E-B562-451F-8D24-8048E2A997C0Q37495206-8D65FBA5-A27F-49FF-ABEE-1180F1DDCE89Q37724957-567FB942-4523-48A1-9BA6-492645D07E8DQ37766940-E1B62106-2458-4565-BBBF-A481BC84A63AQ37784447-75099DF4-E3C6-4566-B0F5-EECA489EC534Q37810104-96E1E8F3-5080-4619-97B7-4E19825938F4Q37829880-C6ECC67D-A648-47AD-A643-A9BEF74B1081Q37840260-0D6F896D-93A9-4CBE-A108-64E444DFCBC3Q37927089-BA3F7FA7-164A-4218-99DF-52065A0EE08EQ38026453-38C3CDA5-FFEB-47E7-BAB7-CAF71B23F40CQ38038645-54D6DEB9-0B74-4A74-B5FC-F12A9D52F565
P2860
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
SU5416, a small molecule tyros ...... or myelodysplastic syndromes.
@en
SU5416, a small molecule tyros ...... or myelodysplastic syndromes.
@nl
type
label
SU5416, a small molecule tyros ...... or myelodysplastic syndromes.
@en
SU5416, a small molecule tyros ...... or myelodysplastic syndromes.
@nl
prefLabel
SU5416, a small molecule tyros ...... or myelodysplastic syndromes.
@en
SU5416, a small molecule tyros ...... or myelodysplastic syndromes.
@nl
P2093
P50
P1433
P1476
SU5416, a small molecule tyros ...... or myelodysplastic syndromes.
@en
P2093
Alison L Hannah
Alison T Stopeck
Anne-Marie O'Farrell
Francis J Giles
Helene A Yuen
Jeffrey E Lancet
Judith E Karp
Julie M Cherrington
Lewis R Silverman
Maureen A Cooper
P304
P356
10.1182/BLOOD-2002-10-3023
P407
P577
2003-03-20T00:00:00Z